Pay in 4 interest-free payments of $5.43 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have transformed the therapeutic landscape of type 2 diabetes (T2D) and obesity by offering substantial weight loss and cardiometabolic protection
But only after careful evaluation of what they offer, what they charge, and what they leave out
Long-Acting GLP-1 RAs Exenatide (Bydureon) In 1987, scientists discovered that GLP-1 promotes insulin secretion, and five years later, an entero-insulin analogue, Exendin-4, which is 53% homologous to GLP-1, was isolated from the saliva of the Mexican giant lizard, later known as exenatide, which has GLP-1 receptor agonist activity and a half-life of 2.4 hours
Lancet 349:698699 Gentile S, Turco S, Guarino G et al (1999) Non-insulin-dependent diabetes mellitus associated with nonalcoholic livercirrhosis: an evaluation of treatment with the intestinal alpha-glucosidase inhibitor acarbose
Can GLP-1 Medications Affect Hormone Therapy Absorption
Unravelling fibrosis using single-cell transcriptomics
US$ 25.22
US$ 23.87
US$ 21.95
